$PFE News and Market Events
Every $PFE story Market Flux has tracked.
- Top Mover
Thermo Fisher Scientific Hits All-Time High of $694.33 Amid Guggenheim Buy Reiteration
Thermo Fisher Scientific shares reached an all-time high of $694.33 on October 15, 2026, as positive analyst sentiment continued to build around the life sciences company. The milestone…
- Top Mover
Pfizer to Present Data From 57 Abstracts at IDWeek 2026 Including Next-Generation Pneumococcal Vaccine Results
Pfizer will showcase data from 57 company-sponsored, investigator-sponsored, and collaborative research abstracts at IDWeek 2026, a major infectious disease congress running October 21-24…
- Most Active
Vaxcyte Surges 50% After VAX-31 Hits All Phase 3 Goals, Launches $1 Billion Capital Raise
Vaxcyte shares surged roughly 50% on October 5 after its 31-valent pneumococcal conjugate vaccine candidate, VAX-31, met all prespecified primary endpoints in OPUS-1, the pivotal adult…
- Top Mover
Morgan Stanley Hosts Major Healthcare Conference, Expands Bitcoin Holdings Past $609 Million and Downgrades Stellantis
Morgan Stanley's 24th Annual Global Healthcare Conference dominated the firm's activity on September 14, drawing presentations from dozens of companies including Eli Lilly, Pfizer, Johnson…
- Market Flux Event
Trump Announces Drug Pricing Deals With Nine More Pharma Companies, Expanding Most Favored Nation Push
President Trump announced on August 31 that his administration has struck drug pricing agreements with nine additional pharmaceutical and biotech companies, committing them to sell…
- Market Flux Event
FDA Clears COVID Vaccines From Pfizer-BioNTech and Moderna for 2026-2027 Season as Priovant Wins Dermatomyositis Approval
The FDA delivered a cluster of drug approvals on August 27, 2026. Pfizer and BioNTech received approval for an updated XFG-adapted formulation of Comirnaty for the 2026-2027 COVID-19…
- Top Mover
Merck and Moderna Phase 3 mRNA Cancer Vaccine Win Lifts Pfizer Stock While Raising Competitive Stakes
Pfizer shares rose about 1% to $27.50 on Wednesday, August 19, bringing the stock's year-to-date gain to roughly 15%, as broad enthusiasm over a landmark cancer vaccine trial lifted the…